CSB Bank Regulatory Approval

Results Update

CSB Bank Results Update

CSB Bank reported Q2 FY27 PAT of ₹183 Crore, up 14% YoY. Deposits and advances grew 18% and 22% YoY respectively.

Earnings Call

CSB Bank Investor Presentation: Key Takeaways

CSB Bank reported Q2 FY27 PAT of ₹183 Cr, up 14% YoY, driven by 20% growth in NII. Advances grew 22% YoY with gold loans comprising 53% of the mix.

Financial Results

CSB Bank Q2 FY27 Results: Net Profit ₹182.7 Cr, Up 14.0% YoY

CSB Bank Ltd reported revenue from operations of ₹1,339 Cr (+20.7% YoY) and net profit of ₹182.7 Cr (+14.0% YoY) for Q2 FY27.

Key figure

Net profit ₹182.7 Cr · +14.0% YoY

Price Movement Clarification

CSB Bank Price Movement Clarification

CSB Bank clarified it is not aware of any merger negotiations with IDBI Bank, responding to a BSE query regarding a recent media report.

Other Announcement

CSB Bank Other Announcement

CSB Bank Ltd has filed its quarterly shareholding pattern disclosure as required under Regulation 31 of the SEBI Listing Regulations.

Board Meeting Date

CSB Bank Board Meeting Date

CSB Bank has scheduled a board meeting on October 23, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026.

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.